Coherus BioSciences, Inc.
CHRS
$0.8343
-$0.076-8.35%
| Weiss Ratings | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | D | |||
| Rating Factors | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.80 | |||
| Price History | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -13.28% | |||
| 30-Day Total Return | -24.32% | |||
| 60-Day Total Return | -48.61% | |||
| 90-Day Total Return | -24.32% | |||
| Year to Date Total Return | -40.54% | |||
| 1-Year Total Return | -65.02% | |||
| 2-Year Total Return | -88.87% | |||
| 3-Year Total Return | -93.71% | |||
| 5-Year Total Return | -94.23% | |||
| 52-Week High % Change | -65.12% | |||
| 52-Week Low % Change | 37.86% | |||
| Price | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.61 | |||
| 52-Week Low Price | $0.66 | |||
| 52-Week Low Price (Date) | Nov 05, 2024 | |||
| 52-Week High Price (Date) | Apr 09, 2024 | |||
| Valuation | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 105.50M | |||
| Enterprise Value | 278.16M | |||
| Price/Earnings (TTM) | 5.89 | |||
| Earnings Per Share (TTM) | 0.15 | |||
| Earnings Per Share Growth | -105.99% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.39 | |||
| Price/Book (Q) | -0.80 | |||
| Enterprise Value/Revenue (TTM) | 1.04 | |||
| Price | $0.83 | |||
| Enterprise Value/EBITDA (TTM) | -3.12 | |||
| Enterprise Value/EBIT | -2.95 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 115.42M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 649 3530 | |||
| Address | 333 Twin Dolphin Drive Redwood City, CA 94065 | |||
| Website | www.coherus.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -35.34% | |||
| Profit Margin | 10.67% | |||
| Management Effectiveness | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -10.94% | |||
| Return on Equity | -- | |||
| Income Statement | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 266.96M | |||
| Total Revenue (TTM) | 266.96M | |||
| Revenue Per Share | $2.31 | |||
| Gross Profit (TTM) | 149.41M | |||
| EBITDA (TTM) | -89.09M | |||
| EBIT (TTM) | -94.37M | |||
| Net Income (TTM) | 28.51M | |||
| Net Income Avl. to Common (TTM) | 28.51M | |||
| Total Revenue Growth (Q YOY) | -40.84% | |||
| Earnings Growth (Q YOY) | 36.35% | |||
| EPS Diluted (TTM) | 0.15 | |||
| EPS Diluted Growth (Q YOY) | 34.87% | |||
| Balance Sheet | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 125.99M | |||
| Cash Per Share (Q) | $1.09 | |||
| Total Current Assets (Q) | 341.58M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -131.99M | |||
| Current Ratio (Q) | 1.207 | |||
| Book Value Per Share (Q) | -$1.14 | |||
| Total Assets (Q) | 448.53M | |||
| Total Current Liabilities (Q) | 282.98M | |||
| Total Debt (Q) | 298.65M | |||
| Total Liabilities (Q) | 580.52M | |||
| Total Common Equity (Q) | -131.99M | |||
| Cash Flow | CHRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 230.32M | |||
| Cash from Financing (TTM) | -186.97M | |||
| Net Change in Cash (TTM) | 22.91M | |||
| Levered Free Cash Flow (TTM) | 41.59M | |||
| Cash from Operations (TTM) | -20.44M | |||
